Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - methylphenidate hydrochloride, quantity: 27 mg - tablet, modified release - excipient ingredients: colloidal anhydrous silica; lactose monohydrate; methacrylic acid copolymer; purified talc; fumaric acid; magnesium stearate; triethyl citrate; hypromellose; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid; titanium dioxide; iron oxide yellow; polyvinyl alcohol; macrogol 3350; indigo carmine aluminium lake - te-methylphenidate xr is indicated for the treatment of attention deficit hyperactivity disorder (adhd). treatment should be commenced by a specialist.,a diagnosis of attention deficit hyperactivity disorder (adhd; dsm-iv) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years.,need for comprehensive treatment programme te-methylphenidate xr is indicated as an integral part of a total treatment program for adhd that may include other measures (psychological, educational and social) for patients with this syndrome. stimulants are not intended for use in the patient who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis. appropriate educational placement is essential and psychosocial intervention is often helpful. when remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physician?s assessment of the chronicity and severity of the patient?s symptoms.,long term use the effectiveness of methylphenidate hydrochloride extended release tablets for long-term use has not been systematically evaluated in controlled trials. therefore the physician who elects to use te-methylphenidate xr for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - methylphenidate hydrochloride, quantity: 54 mg - tablet, modified release - excipient ingredients: purified talc; colloidal anhydrous silica; methacrylic acid copolymer; fumaric acid; magnesium stearate; lactose monohydrate; triethyl citrate; hypromellose; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid; titanium dioxide; iron oxide red; polyvinyl alcohol; macrogol 3350 - te-methylphenidate xr is indicated for the treatment of attention deficit hyperactivity disorder (adhd). treatment should be commenced by a specialist.,a diagnosis of attention deficit hyperactivity disorder (adhd; dsm-iv) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years.,need for comprehensive treatment programme te-methylphenidate xr is indicated as an integral part of a total treatment program for adhd that may include other measures (psychological, educational and social) for patients with this syndrome. stimulants are not intended for use in the patient who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis. appropriate educational placement is essential and psychosocial intervention is often helpful. when remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physician?s assessment of the chronicity and severity of the patient?s symptoms.,long term use the effectiveness of methylphenidate hydrochloride extended release tablets for long-term use has not been systematically evaluated in controlled trials. therefore the physician who elects to use te-methylphenidate xr for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - methylphenidate hydrochloride, quantity: 18 mg - tablet, modified release - excipient ingredients: colloidal anhydrous silica; magnesium stearate; fumaric acid; lactose monohydrate; triethyl citrate; purified talc; methacrylic acid copolymer; hypromellose; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid; titanium dioxide; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - te-methylphenidate xr is indicated for the treatment of attention deficit hyperactivity disorder (adhd). treatment should be commenced by a specialist.,a diagnosis of attention deficit hyperactivity disorder (adhd; dsm-iv) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years.,need for comprehensive treatment programme te-methylphenidate xr is indicated as an integral part of a total treatment program for adhd that may include other measures (psychological, educational and social) for patients with this syndrome. stimulants are not intended for use in the patient who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis. appropriate educational placement is essential and psychosocial intervention is often helpful. when remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physician?s assessment of the chronicity and severity of the patient?s symptoms.,long term use the effectiveness of methylphenidate hydrochloride extended release tablets for long-term use has not been systematically evaluated in controlled trials. therefore the physician who elects to use te-methylphenidate xr for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.

New Zealand - English - Medsafe (Medicines Safety Authority)

te arai biofarma limited - dimethyl fumarate 120mg - modified release capsule - 120 mg - active: dimethyl fumarate 120mg excipient: colloidal silicon dioxide crospovidone sheffcoat clear asa 5x00294 sheffcoat white ent tec 5x00273 capsugel white op/green op c162 magnesium stearate microcrystalline cellulose povidone - indicated in patients with relapsing multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.

New Zealand - English - Medsafe (Medicines Safety Authority)

te arai biofarma limited - zonisamide 100mg - capsule - 100 mg - active: zonisamide 100mg excipient: gelatin hydrogenated vegetable oil microcrystalline cellulose polyethylene glycol hydrogenated castor oil ponceau 4r purified water quinoline yellow titanium dioxide - monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy. adjunctive therapy in the treatment of partial seizures, with or without secondary generalisation, in adults, adolescents, and children aged 6 years and above.

New Zealand - English - Medsafe (Medicines Safety Authority)

te arai biofarma limited - zonisamide 25mg - capsule - 25 mg - active: zonisamide 25mg excipient: gelatin hydrogenated vegetable oil microcrystalline cellulose polyethylene glycol hydrogenated castor oil purified water titanium dioxide - monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy. adjunctive therapy in the treatment of partial seizures, with or without secondary generalisation, in adults, adolescents, and children aged 6 years and above.

New Zealand - English - Medsafe (Medicines Safety Authority)

te arai biofarma limited - zonisamide 50mg - capsule - 50 mg - active: zonisamide 50mg excipient: gelatin hydrogenated vegetable oil iron oxide black microcrystalline cellulose polyethylene glycol hydrogenated castor oil purified water titanium dioxide - monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy. adjunctive therapy in the treatment of partial seizures, with or without secondary generalisation, in adults, adolescents, and children aged 6 years and above.

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - abiraterone acetate, quantity: 250 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; lactose monohydrate; povidone; sodium lauryl sulfate; colloidal anhydrous silica; magnesium stearate; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - te-abiraterone is indicated in combination with prednisolone for the treatment of:,? newly diagnosed high-risk metastatic hormone sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (adt), or,? patients with metastatic advanced prostate cancer (castration resistant prostate cancer, mcrpc) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy (adt) or,? patients with mcrpc who have received prior chemotherapy containing a taxane

Australia - English - Department of Health (Therapeutic Goods Administration)

wai shun pty ltd - gardenia jasminoides, quantity: 50 mg (equivalent: gardenia jasminoides, qty 500 mg); cyperus rotundus, quantity: 50 mg (equivalent: cyperus rotundus, qty 1 g); curcuma zedoaria, quantity: 50 mg (equivalent: curcuma zedoaria, qty 715 mg); bupleurum falcatum, quantity: 40 mg (equivalent: bupleurum falcatum, qty 344 mg); abrus cantoniensis, quantity: 75 mg (equivalent: abrus cantoniensis, qty 1.5 g); hypericum japonicum, quantity: 60 mg (equivalent: hypericum japonicum, qty 1.284 g); inula britannica, quantity: 50 mg (equivalent: inula britannica, qty 625 mg); desmodium styracifolium, quantity: 75 mg (equivalent: desmodium styracifolium, qty 1.605 g) - capsule, hard - excipient ingredients: purified talc; gelatin - traditionally used in chinese medicine to maintain/support natural liver cleansing/detoxification processes ; traditionally used in chinese medicine to helps enhance/promote healthy gallbladder function ; traditionally used in chinese medicine to maintain/support urinary tract health